Le Lézard
Classified in: Business
Subject: BCY

Navillus Receives Approval to Exit Chapter 11


NEW YORK, Oct. 10, 2018 /PRNewswire/ -- Navillus today announced that it has received approval to exit Chapter 11 bankruptcy protection from presiding Bankruptcy Court Judge Sean H. Lane who confirmed Navillus' Plan of Reorganization.  Navillus will exit bankruptcy with an agreed upon settlement with the union parties.

Navillus Logo (PRNewsfoto/Navillus)

"Throughout this process our work has continued uninterrupted and we've remained focused on executing New York City's biggest projects for our clients," said Donal O'Sullivan, Founder and CEO of Navillus Contracting. "Navillus today remains strong as ever with an eye on continued growth in our future."

Throughout the Chapter 11 process, Navillus, which maintains a $750M project workload, has not lost a single contract, retained its executive management team and project managers as well as all relationships with vendors, subcontractors and clients. Today's approval comes as a result of an August settlement Navillus brokered to end its dispute with the unions, which vacated the court's original judgement in its entirety.

"Ultimately, Donal and the Navillus team are highly-regarded by the building industry, unions members, project owners, construction managers and surety providers which paved their way for this successful result," said Christopher Wu, a senior managing director of Teneo Capital who serves as financial advisor to the Company.  "Navillus can now better focus on growing its core business of building super structures, general contracting work and expanding into more infrastructure related projects."

Founded in 1987, Navillus is a New York City-based construction company specializing in commercial concrete, masonry, tile, stone, and general contracting. With more than 30 years of experience and outstanding capabilities in cost estimation, value engineering, and project management, Navillus has played a leadership role in many of the region's most highly recognized and iconic infrastructure and private-sector projects. They have also consistently donated time and resources to communities in need, including assistance with emergency response efforts after recent hurricane Florence, Hurricane Irma, Hurricane Sandy and the 2010 earthquake in Haiti.

Navillus is currently working on several major projects in NYC including:

Navillus' CEO also reaffirmed his appreciation and respect for the tens of thousands of union workers Navillus has employed throughout its 30-year history. 

C. Nathan Dee and Elizabeth Aboulafia of Cullen and Dykman LLP served as lead debtor's counsel.

 

SOURCE Navillus


These press releases may also interest you

at 16:05
Cutera, Inc. ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2024. Consolidated revenue for the first quarter of 2024 of $38.8 million....

at 16:05
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the first quarter ended March 31, 2024...

at 16:05
Everbridge, Inc. , the global leader in critical event management (CEM) and national public warning solutions, today announced its financial results for the first quarter ended March 31, 2024. Revenue for the first quarter was up 3% year-over-year to...

at 16:05
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m....

at 16:05
Expensify, Inc. , a payments superapp that helps individuals and businesses around the world simplify the way they manage money across expenses, corporate cards and bills, today released a letter to shareholders from Founder and CEO David Barrett...

at 16:05
Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On...



News published on and distributed by: